Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun;10(3):378-384.
doi: 10.1016/j.tranon.2017.03.005. Epub 2017 Apr 19.

Serum MicroRNAs Related with Chemoradiotherapy Resistance in Advanced-Stage Cervical Squamous Cell Carcinoma

Ying Han  1 , Mei Liu  2 , Ziyi Wang  3 , Manni Huang  1 , Ningzhi Xu  4 , Lingying Wu  5
Affiliations

Serum MicroRNAs Related with Chemoradiotherapy Resistance in Advanced-Stage Cervical Squamous Cell Carcinoma

Ying Han et al. Transl Oncol. 2017 Jun.

Abstract

Objective: To investigate the serum microRNAs as biomarkers in predicting chemoradiotherapy resistance in advanced-stage cervical squamous cell carcinoma (ACSCC) patients.

Methods: Serum samples were collected from International Federation of Gynecology and Obstetrics (FIGO) stage IIB to IIIB cervical squamous cell carcinoma patients treated with platinum based Concomitant Chemoradiotherapy (CCRT) in our hospital during September 2013 to November 2015. Twenty well-matched samples (10 resistant and 10 sensitive) were chosen to screen the miRNA expression profile using serum samples pooled with microarrays. miRNAs expressed significantly different between two groups were further verified in 131 patients (29 resistant and 102 sensitive) serum samples with TaqMan Real-time PCR. The AUC was used to evaluate the accuracy of the biomarkers for prediction.

Results: MiR-136-5, miR-152-3p and miR-206 were expressed significantly different between sensitive and resistant groups. Results of 131 patients verification showed that the levels of miR-206 in sensitive samples and resistant samples were 2.715±0.2115 and 14.64±1.184, respectively, which was significantly different (P<.0001), while miR-136-5p and miR-152-3p could not be tested without pre-amplification reactions. Univariate analysis revealed that miR-206 expression was significantly associated with patients' DFS. Multivariate analysis demonstrated that miR-206 expression, tumor differentiation and pelvic lymph nodes metastasis were the independent prognostic factors associated with DFS in this cohort (P=.008, 0.000, 0.000, respectively). The probability of the prognostic accuracy of miR-206 expression in predicting chemoradiotherapy sensitivity of ACSCC patients was 91.3% (79.3% sensitivity and 92.2% specificity).

Conclusion: Serum miR-206 is a powerful tool in predicting chemoradiotherapy sensitivity in ACSCC patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of the screening and verifying processes. TaqMan Real-time PCR microRNA Array (Card A) (Applied Biosystems, CA) representing 212 mature miRNAs was used to identify differentially expressed miRNAs from 20 serum samples (10 from sensitive group vs. 10 from resistant group). Take miRNA expression in sensitive group as standard, a total of 62 miRNAs were up-regulated expression while 150 miRNAs were down-regulated expression in resistant group. Among these miRNAs, 3 miRNAs expressed statistically significantly different between two groups. MiR-136 was down-regulated expression in resistant group while miR-152 and miR-206 was up-regulated expression. Three candidate miRNAs were further validated in 131 independent serum samples.
Figure 2
Figure 2
The scatter diagrams of serum miR-206 in 131 ACSCC patients. Resistant group includes 29 cases, sensitive group includes 102 cases.
Figure 3
Figure 3
The level of serum miR-206 was associated with disease free survival.
Figure 4
Figure 4
ROC analysis for predicting CCRT sensitivity of ACSCC patients: (A) ROC curve for miR-206 yielded area under the curve (AUC) of 91.3%, the sensitivity of 79.3% and specificity of 92.2% in predicting chemoradiotherapy sensitivity; (B) ROC curve for tumor differentiation (TD) and pelvic lymph nodes metastasis (PLNM) yielded an AUC of 76.5%, the sensitivity of 82.8% and specificity of 57.8% in predicting chemoradiotherapy sensitivity.
See this image and copyright information in PMC

References

    1. International Agency for Research on Cancer . World Health Organization; 2012. Cervical Cancer Estimated Incidence, Mortality and Prevalence Worldwide in 2012.
    1. Morris M, Eifel PJ, Lu J, Grigsby PW, Levenback C, Stevens RE, Rotman M, Gershenson DM, Mutch DG. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med. 1999;340(15):1137–1143. - PubMed
    1. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, Clarke-Pearson DL, Insalaco S. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340(15):1144–1153. - PubMed
    1. Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL, 3rd, Walker JL, Gersell D. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999;340(15):1154–1161. - PubMed
    1. Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC, Jr, Clarke-Pearson DL, Liao SY. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999;17(5):1339–1348. - PubMed

LinkOut - more resources